Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in High-Risk Head and Neck Cancer
NCT01810913Phase 3Suspended
- Sponsor
- National Cancer Institute
- Start
- Mar 2013
- Primary completion
- Jan 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of atezolizumab, KL-140, docetaxel in head and neck squamous cell carcinoma (HNSCC), sponsored by National Cancer Institute. Started Mar 2013; status: suspended.
02
Drugs
atezolizumabKL-140docetaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01810913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01810913.